Sanofi Shares Outstanding 2006-2018 | SNY

Sanofi shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Sanofi shares outstanding for the quarter ending March 31, 2018 were 2.496B, a 1.12% decline year-over-year.
  • Sanofi 2017 shares outstanding were 2.534B, a 2.25% decline from 2016.
  • Sanofi 2016 shares outstanding were 2.592B, a 1.87% decline from 2015.
  • Sanofi 2015 shares outstanding were 2.641B, a 0.78% decline from 2014.
Sanofi Annual Shares Outstanding
(Millions of Shares)
2017 2,534
2016 2,592
2015 2,641
2014 2,662
2013 2,675
2012 2,656
2011 2,643
2010 2,611
2009 2,612
2008 2,611
2007 2,694
2006 1,347
2005 2,673
Sanofi Quarterly Shares Outstanding
(Millions of Shares)
Q1 2018 2,496
Q4 2017 2,534
Q3 2017 2,509
Q2 2017 2,516
Q1 2017 2,525
Q4 2016 2,592
Q3 2016 2,577
Q2 2016 2,574
Q1 2016 2,577
Q3 2015 2,611
Q2 2015 2,612
Q2 2014 2,634
Q2 2013 2,691
Q2 2012 2,631
Q1 2012 2,642
Q4 2011 2,660
Q3 2011 2,678
Q2 2011 2,588
Q1 2011 2,614
Q4 2010 2,610
Q3 2010 2,610
Q2 2010 2,606
Q1 2010 2,609
Q4 2009 2,614
Q3 2009 2,611
Q2 2009 2,611
Q1 2009 2,609
Q4 2008 2,401
Q3 2008 2,616
Q2 2008 2,623
Q1 2008 1,320
Q4 2007 2,671
Q3 2007 2,705
Q2 2007 2,704
Q1 2007 2,702
Q4 2006 2,696
Q3 2006 2,698
Q2 2006 2,692
Q1 2006 2,701
Q4 2005 2,674
Q3 2005 1,333
Q2 2005 2,672
Q1 2005 1,335
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $112.713B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
Novartis AG (NVS) Switzerland $204.655B 17.49
AbbVie (ABBV) United States $134.597B 11.95
Eli Lilly (LLY) United States $122.680B 21.57
Novo Nordisk (NVO) Denmark $111.107B 18.04
AstraZeneca (AZN) United Kingdom $103.342B 12.83
GlaxoSmithKline (GSK) United Kingdom $101.256B 13.61
Bristol-Myers Squibb (BMY) United States $87.290B 14.38